Lung Adenocarcinoma Treatment Market To Reach $11.18 Billion By 2030

Lung Adenocarcinoma Treatment Market Growth & Trends

The global lung adenocarcinoma treatment market size is expected to reach USD 11.18 billion by 2030, registering a CAGR of 10.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms. 

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

 Request a free sample copy or view report summary: Lung Adenocarcinoma Treatment Market Report

Lung Adenocarcinoma Treatment Market Report Highlights

• The chemotherapy segment accounted for the largest revenue share of 36% in 2024. This is primarily due to its established role in lung cancer management and ongoing advancements in treatment regimens.

• The immunotherapy segment is expected to witness the fastest growth, with a projected CAGR of 13.5% over the forecast period. The rising prevalence of lung adenocarcinoma has increased the demand for advanced treatment options that offer better efficacy and safety compared to traditional therapies such as chemotherapy and radiation.

• Hospitals accounted for the largest revenue share of 63.9% in 2024, driven by their comprehensive infrastructure and ability to provide a wide range of advanced cancer treatments.

• The specialty clinics segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the rising demand for personalized and targeted therapies, along with increasing patient awareness of lung cancer treatment options.

• North America lung adenocarcinoma treatment market held the largest revenue share of 39.5% in 2024, driven by the rising incidence of lung adenocarcinoma and a strong focus on innovation in treatment approaches.

Lung Adenocarcinoma Treatment Market Segmentation

Grand View Research has segmented global lung adenocarcinoma treatment Market report based on treatment, end-use, and region: 

Lung Adenocarcinoma Treatment Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Targeted Therapy

• Immunotherapy

• Radiation Therapy

• Others

Lung Adenocarcinoma Treatment End-use Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Specialty Clinics

• Others

Lung Adenocarcinoma Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Lung Adenocarcinoma Treatment Market

• Pfizer Inc.

• AstraZeneca

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• Boehringer Ingelheim International GmbH

• Novartis AG

• Merck KGaA (EMD Serono)

• AbbVie Inc.

• Astellas Pharma Inc.

• F. Hoffmann-La Roche Ltd